conference reporter

ASCO20 Virtual Scientific Program and the Virtual Edition of the 25th EHA Annual Congress

Conference Reporter in Multiple Myeloma to Cover Key Topics Being Presented at the ASCO20 Virtual Scientific Program and the Virtual Edition of the 25th EHA Annual Congress

by Tom Iarocci, MD

Overview

Conference Reporter delivers health care providers with insights from key thought leaders on exciting news presented at major medical conferences, in a concise and timely format. This issue of Conference Reporter will feature coverage of selected topics in Multiple Myeloma presented at this year's ASCO and EHA annual meetings.

"Whether you are able to attend the virtual sessions or not, Conference Reporter in Multiple Myeloma will enhance your on-demand conference experience."

Tom Iarocci, MD

The oncologists who were surveyed selected the following expert commentators and topics from the upcoming conferences.

Community-Selected Expert Commentators:

Robert Z. Orlowski, MD, PhD

Director of Myeloma Section
Department of Lymphoma/Myeloma
Florence Maude Thomas Cancer Research Professor
Department of Experimental Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

S. Vincent Rajkumar, MD

Edward W. and Betty Knight Scripps Professor of Medicine
Mayo Clinic
Rochester, MN

Paul G. Richardson, MD

Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, MA

Community-Selected Topics:

  • Multiple Myeloma Session Roundup: Measurable Residual Disease Assessment and Implications
  • Treatment of Patients With Relapsed/High-Risk Multiple Myeloma
  •  Clinical Considerations in Initial Treatment of Newly Diagnosed Patients With Multiple Myeloma
  •  Novel Agents in the Approach to Patients With High-Risk Multiple Myeloma
  •  Refractory Multiple Myeloma: Tailoring Treatment to Patient Characteristics
  •  CD38 and Its Expanding Role as an Immunomodulator and Druggable Target


This information is brought to you by Engage Health Media and is not sponsored by, nor a part of, the American Society of Clinical Oncology or the European Hematology Association.

More in Multiple Myeloma

Thumb

Multiple Myeloma

Multiple Myeloma Session Roundup: Minimal Residual Disease Assessment and Implications

Conference Reporter by Robert Z. Orlowski, MD, PhD; S. Vincent Rajkumar, MD; and Paul G. Richardson, MD

Several abstracts and posters on minimal residual disease (MRD) in multiple myeloma were presented at theĀ ASCO20 Virtual Scientific Program, in the...READ MORE

Thumb

Multiple Myeloma

Treatment of Patients With Relapsed and/or Refractory and High-Risk Multiple Myeloma

Conference Reporter by Robert Z. Orlowski, MD, PhD; S. Vincent Rajkumar, MD; and Paul G. Richardson, MD

Several abstracts and posters focused on relapsed/refractory and high-risk multiple myeloma were presented at the ASCO20 Virtual Scientific Program...READ MORE

Thumb

Multiple Myeloma

Clinical Considerations in Initial Treatment of Newly Diagnosed Patients With Multiple Myeloma

Conference Reporter by Robert Z. Orlowski, MD, PhD; S. Vincent Rajkumar, MD; and Paul G. Richardson, MD

Emerging comparative data with carfilzomib, lenalidomide, and dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) in the initi...READ MORE

More In Conference Reporter

Metastatic Prostate Cancer

Promise in Treatment Personalization for Advanced Prostate Cancer

Conference Reporter
by E. David Crawford, MD

Metastatic Prostate Cancer

Metastatic Prostate Cancer: Predictive Biomarkers for Tailored Therapy

Conference Reporter
by E. David Crawford, MD

Metastatic Prostate Cancer

Novel and Emerging Treatments for Progressive Metastatic Castration-Resistant Prostate Cancer

Conference Reporter
by William K. Oh, MD